How Boston Scientific stock looks after recent performance

Boston Scientific (BSX) has drawn attention after its share price return over the past month and past three months, alongside a one-year total return of an 8.63% decline and a three-year total return near 9.28x.

With the share price at $93.53, recent trading has been slightly soft over the past quarter but sits against a far stronger backdrop. The 3 year total shareholder return of 92.85% and 5 year total shareholder return of 140.07% point to a much more constructive long term picture.

If Boston Scientific has you looking at the wider health sector, it could be a useful moment to scan for other ideas through healthcare stocks and see what else fits your criteria.

Recent returns have cooled, yet Boston Scientific still carries a strong multi year track record. Analyst targets also sit well above the current US$93.53 price. Is this a genuine opening, or is future growth already priced in?

Most Popular Narrative: 25.4% Undervalued

Boston Scientific's most followed narrative puts fair value at about $125.45 per share compared with the recent $93.53 close, and ties that gap to a detailed earnings and margin roadmap.

Enhanced scale and operational efficiency through supply chain initiatives, digitalization, and manufacturing automation, alongside robust cash flow, positions Boston Scientific to expand operating margins and generate sustainable earnings growth over the long term.

Curious what earnings path and margin profile are baked into that fair value, and how rich a future P/E the narrative leans on? The full story spells out the growth, profitability and valuation assumptions that need to line up for that target to make sense.

Result: Fair Value of $125.45 (UNDERVALUED)

However, there are clear watchpoints, including ongoing tariff and reimbursement pressures, as well as tougher competition in key product areas, that could challenge this optimistic setup.

Another Take On Valuation

That 25.4% “undervalued” fair value hinges on growth and margin assumptions, but the current P/E of 49.7x tells a different story. It is higher than both the US Medical Equipment industry at 31.1x and the 40.7x fair ratio our model suggests the market could move toward. If sentiment cools, would the share price need to adjust, or would the earnings outlook need to do more of the work?

Build Your Own Boston Scientific Narrative

If you see the numbers differently or prefer to test your own assumptions, you can build a personalised Boston Scientific view in just a few minutes with Do it your way.

A great starting point for your Boston Scientific research is our analysis highlighting 3 key rewards and 1 important warning sign that could impact your investment decision.

Looking for more investment ideas?

If you stop at just one company, you could miss other opportunities that fit your style, so use the screener to widen your options with focus.

• Start spotting early stage growth stories with these 3527 penny stocks with strong financials that already show stronger financial underpinnings than many of their peers.
• Tap into the potential of automation and machine learning in healthcare by scanning these 110 healthcare AI stocks for companies shaping digital care and diagnostics.
• Hunt for income ideas that go beyond cash in the bank by checking these 12 dividend stocks with yields > 3% for companies offering yields above 3%.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.